Can low thyroid hormone signaling cause low energy and an atherogenic lipid pattern?

Thyroid hormone (specifically triiodothyronine, or T3) is a master metabolic regulator, directly coordinating mitochondrial energy production and hepatic lipid clearance.

Cellular energetics and fatigue

• Mitochondrial dysfunction: Low thyroid signaling down-modulates mitochondrial biogenesis and oxidative phosphorylation (OXPHOS) gene transcription (via PGC-1α), reducing skeletal muscle ATP availability. This forces an earlier transition to anaerobic glycolysis and elevated lactate during exertion, manifesting as physical fatigue.
• Inflammatory and systemic effects: Elevated TSH in subclinical states can promote inflammatory cytokines (such as IL-1β and IL-6) and exacerbate insulin resistance, further hindering metabolic flexibility and glucose utilization.
• Clinical response: Six months of levothyroxine (LT4) therapy reduces fatigue in overt hypothyroidism, but trials show no benefit over placebo in subclinical cases. Furthermore, 25% of overt patients experience persistent fatigue despite achieving biochemical euthyroidism.

Mechanistic basis of lipid accumulation

• Impaired receptor clearance: Reduced T3 signaling decreases hepatic low-density lipoprotein receptor (LDLR) transcription via thyroid hormone-responsive elements and SREBP-2. Receptor clearance is further compromised by reduced LRP1 and elevated PCSK9-mediated LDLR degradation.
• Reduced lipase activity: Deficient thyroid signaling decreases lipoprotein lipase (LPL) and hepatic lipase (HL) activity, impairing the hydrolysis of triglyceride-rich VLDL and chylomicrons.
• Atherogenic profile: The combined loss of LDLR-mediated endocytosis and lipase activity restricts the hepatic uptake and catabolism of LDL, IDL, and remnant particles, directly elevating circulating total cholesterol, LDL-C, and triglycerides.

Bottom line

• Low thyroid hormone signaling drives physical fatigue through impaired mitochondrial OXPHOS and generates an atherogenic lipid profile by downregulating LDLR, LPL, and HL. Hormone replacement resolves these metabolic deficits in overt hypothyroidism, but does not reliably reverse fatigue in subclinical cases.